Navigation Links
Study of gene transfer for erectile dysfunction shows promise

The first human study using gene transfer to treat erectile dysfunction (ED) shows promising results and suggests the potential for using the technology to treat overactive bladder, irritable bowel syndrome and asthma, according to the researchers.

"In the small pilot study, this new therapy was well tolerated and safe," said George Christ, Ph.D., senior researcher and a professor at the Institute for Regenerative Medicine at Wake Forest University School of Medicine. "It provides evidence that gene transfer is a viable approach to treating ED and other diseases involving smooth muscle cells."

The results of the study, which included 11 men with ED, are reported online today in Human Gene Therapy. The technology was developed by Christ and Arnold Melman, M.D., when they worked together at Albert Einstein College of Medicine in the Bronx, New York.

Unlike traditional gene therapy, the gene transfer approach being pioneered by Christ and Melman does not change the DNA or genetic code of cells. Instead, small pieces of DNA reach the nuclei of cells and this causes them to increase production of particular proteins. These proteins help relax smooth muscle cells, the type of muscle found in the penis as well as in hollow organs such as the bladder. Relaxing the tissue allows the penis to fill with blood and become erect.

Previous research has shown that more than 50 percent of men between 40 and 70 years old and 70 percent over age 70 may have ED. The new therapy is a potential alternative to oral medications, such as Viagra, which are not effective for an estimated 30 to 40 percent of men with ED.

A possible advantage of gene transfer is that a single treatment could last for months. In the current study, improvements were maintained through the 24 weeks of study.

The study was conducted from May 2004 to May 2006 at Mount Sinai School of Medicine and New York University School of Medicine. Men ranged from 42 to
'"/>

Source:Wake Forest University Baptist Medical Center


Page: 1 2 3

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works

Post Your Comments:
(Date:11/5/2009)...ty have developed synthetic molecules capable of e...-infected cells, as well as to prostate cancer cel...al of the American Chemical Society , could lead t... , The molecules called "antibody-recruiting m...iting molecule targeting prostate cancer" (ARM-P) ...
(Date:11/4/2009)...g Beach and Riverside are responsible for a signif...and the true impact of air pollution and ship emis...d, according to researchers at the University of S...pears in an online edition of the American Journa...f all childhood asthma cases in Long Beach and six...
(Date:11/4/2009)...eived more than $10 million in research grants fro...mulus program, bringing thetotal amount of stimulu...n. Thirty-three projects achieved stimulus fundin... , "The university has thoughtfully undertaken a... excellence to federal agency priorities. Through...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2USC study finds big air pollution impacts on local communities 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Zimmer Holdings to Present at Upcoming Investor Conferences 55934 1DIA Conference to Explore The Science and Scope of Personalized Medicine 55930 1DIA Conference to Explore The Science and Scope of Personalized Medicine 55930 2U S Labor Department announces dates for 4th annual Drug Free Work Week 55926 1U S Labor Department announces dates for 4th annual Drug Free Work Week 55926 2
...nced Identification Systems/Commerc... 28 /PRNewswire-FirstCall/-- Atmel (Nasdaq:,ATML),...ns, announced today,that Kerry Maletsky, Business ...nt "Secure Biometric Co-processor: Solving the Net...on Systems/Commercial Biometrics,Conference in Was...
...MEA spurs IdentiPHI,s company ...tiPHI, Inc., an innovative,leader in enterprise se...sion with the opening of an office in Paris to add...identity and authentication (access,management) pr...ope will enable us to more closely serve our,growi...
...cans are an increasingly used X-ray-based tool for...r organ or tissue. The value of CT scanning to dia...undisputed. But are these scans being used too fre... health consequences of having too many CT scans o... 2007 article in The New England Journal of Medici...
Other Biology News:Atmel's Biometric Co-processor Solution Featured at AIS/CBX 2IdentiPHI Opens Paris Office to Boost European Sales and Support 2Columbia researchers: Growth of CT scan use may lead to significant public health problem 2Columbia researchers: Growth of CT scan use may lead to significant public health problem 3
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 Personali... to take place on February 22-24, 2010 in Philadel...ence we will highlight key issues in forming partn...r experiences. , Minneapo... Arrowhead’s 2010 Personalized Medicine Par...
(Date:11/5/2009)... Nov. 5 DSM Pharmaceutical Product... alliance with Galenix, Saint Jean D,Illac, France... manufacturing partner for Galenix commercial prod... collaborate on business development opportunities...based on the strength of Galenix in drug product d...
(Date:11/5/2009)... 5 Transgenomic, Inc. (O... results for the quarter ended September 30, 2009....the tables that follow. ,, Third Quarter 2009 ... or $0.01 per share for the third quarter of 2009 ... share for the third quarter of 2008. ,, Net s...
(Date:11/5/2009)...vember 5, 2009 Senomyx, ...proprietary taste receptor-based technologies to d...erage, and ingredient supply industries, today pro...sults for the third quarter ended September 30, 20...ter of 2009, compared to $4.0 million for the thir...
Breaking Biology Technology:Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
...lix BioPharma Corp. (TSX, FSE: "HBP") today announ...scal 2009, ended January 31, 2009. , , RECENT H...-F registration statement with the U.S. Securities... March 12, 2009 , , , , , , Helix...European Phase II pharmacokinetic study in human s...
... Protocol Driven Healthcare , Inc. (PDHI) now of...(HRA), the ConXus(R) Profile. The shorter format f...racy and reduces processing costs of paper assessm..., longer adult HRA, but joins PDHI,s suite of Con...students, children, and Spanish-speaking adults. ...
...nership Will Increase Productivity to Meet Growing... Indonesia (PRWEB) March 16, 2009 -- DuPont and ...oday announced an agreement that grants DuPont bus...ialize ICRR rice hybrids in Asia. , , , , ,Rice is... of the world,s population. The growing populatio...
Other Biology Technology:Helix BioPharma Announces Q2 2009 Financial Results 2Helix BioPharma Announces Q2 2009 Financial Results 3Helix BioPharma Announces Q2 2009 Financial Results 4Helix BioPharma Announces Q2 2009 Financial Results 5Helix BioPharma Announces Q2 2009 Financial Results 6Helix BioPharma Announces Q2 2009 Financial Results 7Helix BioPharma Announces Q2 2009 Financial Results 8Helix BioPharma Announces Q2 2009 Financial Results 9Helix BioPharma Announces Q2 2009 Financial Results 10Helix BioPharma Announces Q2 2009 Financial Results 11Helix BioPharma Announces Q2 2009 Financial Results 12PDHI Launches Short Form of Its ConXus Profile Health Assessment 2DuPont Partners with Indonesian Center for Rice Research to Advance Hybrid Rice 2DuPont Partners with Indonesian Center for Rice Research to Advance Hybrid Rice 3
Mouse Anti-IFN-alpha2 Monoclonal Antibody, Fluorescein isothiocyanate (FITC) Conjugated, Clone 225.C from eBioscience
Mouse Anti-alpha Sodium Potassium ATPase Monoclonal Antibody, Unconjugated, Clone M7-PB-E9 from Abcam
Rabbit Anti-Human SP2 Polyclonal Antibody, Unconjugated from Atlas Antibodies
Rabbit Anti-Asparagine synthetase Monoclonal Antibody, Unconjugated, Clone EP282Y from Abcam
Biology Products: